GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » Book Value per Share

Horizon Therapeutics (Horizon Therapeutics) Book Value per Share : $23.20 (As of Jun. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics Book Value per Share?

Horizon Therapeutics's book value per share for the quarter that ended in Jun. 2023 was $23.20.

During the past 12 months, Horizon Therapeutics's average Book Value Per Share Growth Rate was 8.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 24.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 33.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Horizon Therapeutics was 68.60% per year. The lowest was -5.00% per year. And the median was 23.65% per year.

Horizon Therapeutics's current price is $116.30. Its book value per share for the quarter that ended in Jun. 2023 was $23.20. Hence, today's PB Ratio of Horizon Therapeutics is 5.01.

During the past 13 years, the highest P/B Ratio of Horizon Therapeutics was 14.90. The lowest was 1.07. And the median was 3.34.


Horizon Therapeutics Book Value per Share Historical Data

The historical data trend for Horizon Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Book Value per Share Chart

Horizon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.05 11.62 18.19 20.55 22.32

Horizon Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.47 22.01 22.32 22.29 23.20

Competitive Comparison of Horizon Therapeutics's Book Value per Share

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horizon Therapeutics's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's PB Ratio falls into.



Horizon Therapeutics Book Value per Share Calculation

Horizon Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(5,072-0)/227
=22.32

Horizon Therapeutics's Book Value Per Share for the quarter that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(5,311-0)/229
=23.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Horizon Therapeutics  (NAS:HZNP) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Horizon Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (Horizon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Executives
Andy Pasternak officer: EVP and Chief Business Officer C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox officer: EVP, Chief Financial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman officer: EVP & Chief Medical Officer C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny officer: Chief Accounting Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton officer: EVP, General Counsel C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z. officer: EVP, Research & Development C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director, officer: President, Chairman and CEO 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi officer: Chief Commercial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher officer: EVP Finance 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin officer: EVP, Technical Operations C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh officer: Principal Accounting Officer C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze officer: EVP, Corporate Dev't. C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler officer: EVP, General Counsel C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel director TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000